Dabigatran (Pradaxa in Australia, Europe, USA and Canada; Prazaxa in Japan) is an oral anticoagulant from the class of the direct thrombin inhibitors.  It is used for various<unk>  indications, and in some cases it offers an alternative to warfarin as the preferred orally administered anticoagulant ("blood thinner"), since it does not require frequent blood tests for international normalized ratio monitoring, while offering similar results in terms of efficacy.  Unlike warfarin, no specific way exists to reverse the anticoagulant effect of dabigatran in the event of a major bleeding event.
Clinical Pharmacology of Dabigatran
Thrombophilia cost-effectiveness of therapy
Estimates of Cost Per Year of Life Saved for Dabigatran
Coagulation factor IX, GlycoPEGylated 
Thrombophilia classification
Fibrin degradation product
Heparin-induced thrombocytopenia cost-effectiveness of therapy
Deep vein thrombosis cost-effectiveness of therapy